Agilent Technologies Expands Therapeutic Nucleic Acids Manufacturing Capacity (09 May 2008) Dow Nucleic Acids Medicines Business Assets Acquired of the assets of its Nucleic Acid Medicines business. The financial terms of the purchase... of Dow's assets will allow Agilent to respond to this demand well ahead of our...
Microbix to spin off Urokinase into newly formed Klarogen Biotherapeutics (09 May 2008) Klarogen to acquire all remaining Urokinase inventory, sales and marketing infrastructure and NDA from ImaRx upon completion of financing assets into a new private company, Klarogen Biotherapeutics Inc., which would..., Klarogen would purchase the Urokinase assets of ImaRx Therapeutics, Inc. of Tuscon, Arizona, for $17 million. These assets would include ImaRx' remaining Urokinase...
ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates (10 Mar 2008) of ActivBiotics, confirmed that the sale of ActivBiotics' proprietary assets... due diligence, I believe we'll be able to successfully monetize the assets... are interested in different assets, it is unlikely that sale of all three assets will go...
Innogenetics announces the intention to restructure its subsidiary GENimmune (14 Feb 2008)
Last year, Innogenetics decided to focus on the development and sales of diagnostic products, and GENimmune N.V. was incorporated as a fully owned subsidiary. GENimmune obtained assets of Innogenetics in the field of drug development...
Top